Barr Files Documents for Pliva Buy

Drugmaker Barr Pharmaceuticals ( BRL) said Friday that it made all the required filings with the U.S. Federal Trade Commission and German regulators regarding its proposed acquisition of Pliva, a generic drugmaker based in Croatia.

Barr has offered about $2.3 billion for Pliva, but Iceland's Actavis Group is also trying to buy the company for the same amount.

''We are hoping for an expedited review and intend to pursue the issuance of our formal tender offer to acquire Pliva in accordance with Croatian takeover law and the Croatian Financial Services Supervisory Agency's instructions as expeditiously as possible," Barr, of Woodcliff Lake, N.J., said in a press release.

Shares of Barr were down 42 cents, or 0.9%, at $46.96.

This story was created through a joint venture between TheStreet.com and IRIS.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says